MedRx Co. Ltd. announced consolidated earnings results for the first quarter ended March 31, 2017. For the period, the consolidated company reported net sales of ¥18 million, operating loss of ¥212 million, ordinary loss of ¥222 million, net loss attributable to owners of the parent of the company of ¥192 million or net loss per basic share of ¥22.61 compared to net sales of ¥9 million, operating loss of ¥268 million, ordinary loss of ¥256 million, net loss attributable to owners of the parent of the company of ¥236 million or net loss per basic share of ¥33.33 for the same period last year.

For the six months ending June 30, 2017, the consolidated company expects net sales of ¥17 million, operating loss of ¥514 million, ordinary loss of ¥499 million, loss attributable to owners of the parent of the company of ¥459 million or net loss per share of ¥53.92.

For the fiscal year ending December 31, 2017, the consolidated company expects net sales of ¥186 million, operating loss of ¥186 million, ordinary loss of ¥1,244 million, loss attributable to owners of the parent of the company of ¥1,206 million or net loss per share of ¥141.70.